Following this approach, many other drugs, such as the PLK1 inhibitor BI 2356, the HAUSP inhibitor P22077, and the PA2G4 inhibitor WS6, are providing the basis for drug design of small molecules targeting Myc and N-Myc binding partners in malignancies driven by MYC family oncoproteins, representing new alternative forms for the treatment of high-risk NB [203,228,229]. This evidence concerns the gene MYC and neuroblastoma.